Physician profile
Ellen M Grimm
NPI 1275500100
$1,325.61
in general payments reported to CMS, 2019-2025
15 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $98.09 · 2022: $511 · 2023: $194 · 2024: $282 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.45 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $274.31 | 2019-2025 | Nxstage System One, Crit-Line, Pureflow Sl |
| Astrazeneca Pharmaceuticals LP | $171.03 | 2019-2024 | Lokelma, Farxiga |
| Boston Scientific Corporation | $157.34 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $139.46 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $137.25 | 2022 | |
| Vifor Pharma, INC. | $129.50 | 2022 | |
| Amgen INC. | $88.95 | 2019-2022 | |
| Medtronic, INC. | $68.40 | 2023 | Ellipsys Vascular Access System |
| Bayer Healthcare Pharmaceuticals INC. | $40.84 | 2021 | |
| Outset Medical INC | $25.44 | 2023 | |
| Ardelyx, INC. | $23.26 | 2024 | Ibsrela |
| Nxstage Medical, INC. | $20.25 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.43 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $16.25 | 2021 | |
| Shield Therapeutics INC | $15.90 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.